Molecular therapy for  pulmonary arterial hypertension (PAH): Exemestane (brand name Aromasin), a drug used to treat breast cancer, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 26/August/2018, 11.03 pm

Serelaxin (SLX)-based therapy for cardiomyocyte proliferation and heart regeneration: Serelaxin (SLX), a recombinant relaxin-2, decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/August/2018, 7.10 pm
August 26, 2018
Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: PCGF2/Mel-18 increases the expression of tumor suppressors genes, such as  BigH3, TIBE2,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 26/August/2018, 11.07 pm
August 26, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journalNature Medicine[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy for pulmonary arterial hypertension (PAH): Exemestane (brand name Aromasin), a drug used to treat breast cancer, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3


The significance of the study:  

This study suggests, first the first time, Exemestane, an anticancer drug, may attenuate pulmonary arterial hypertension.

Exemestaneby increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, exemestane or its cost-effective analogs, either alone or in combination with other drugs,”may be used to treat pulmonary arterial hypertension (Fig. 2). 

Figure 1. Mechanistic insights into how exemestane may function as an anti-pulmonary arterial hypertensive agent.  Exemestane may promote insulin sensitivity and protect against myocardial infarction, via up-regulation of reprogramming protein Lin-28

Figure 2.   Exemestane may inhibit pulmonary arterial hypertension through down-regulation of Notch-3 and its target gene Hes5

 


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How  Exemestane  decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L., Molecular therapy for  pulmonary arterial hypertension (PAH): Exemestane (brand name Aromasin), a drug used to treat breast cancer, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 26/August/2018, 11.03 pm,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.